Mabwell Establishes a Licensing and Commercialization Agreement for Denosumab Biosimilars in Malaysian Market

B SHANGHAI, April 16, 2026 /PRNewswire/ — Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has established a…
posteditor
posteditor
Articles: 16137

Other News